KALLMANN NEUROLOGIE
KALLMANN NEUROLOGIE
Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Sciences 1992 ; 51: 671 – 678
Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity. FEBS Lett. 1992 ; 313: 56-58
Nitric oxide as a mediator of autoimmunity in insulin-dependent diabetes. Immunobiology 1992; 186 : 19 - 20
Interleukin-10 is a predominant cytokine in atopic dermatitis. Archives of Dermatology 1996; 132: 1133-1134
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves‘ disease. Diabetes 1997; 46: 237-243
Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Multiple Sclerosis 1998; 4: 178-182
Cytokine secretion patterns in twins discordant for type I diabetes. Diabetelogia 1999; 42: 1080-1085
Exogenous nitric oxide modulates cytokine production in human leucocytes. Life Sciences 1999; 65: 1787-1794
Immunological parameters and magnetic resonance imaging activity. Frontiers in Multiple Sclerosis 1999; 2, Ed. A.Siva, J.Kesselring, A.J.Thompson, Martin Dunitz Ltd.: 117-125
Pathogenesis and therapeutic concepts of organ-specific autoimmune diseases. Autoimmunity 1999; 31: 283-288
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000; 123: 687-697
The production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules. Journal of Neuropathology and Experimental Neurology 2001; 60: 320-327
Immunmodulatorische Stufentherapie der Multiplen Sklerose. 1. Ergänzung: Dezember 2000. Nervenarzt 2001; 72: 150-157
Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 2002; 73: 556-563
Characteristic gene expression profile of primary human cerebral endothelial cells.FASEB J Express, February 12, 2002, 10.1096/fj.01-0594fje
Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine 2002; 19 (2): 55-58
Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. Multiple Sclerosis 2002; 8: 523-526
UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum. RNA 2002; 8: 1538-1547
Chemokines and MS lesion development. International Journal of Multiple Sclerosis 2002; 9: 100-107
Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurology 2002; 1: 499-509
Was gibt es Neues in der Multiplen Sklerose? Akt Neurologie 2003; 30: 421-427
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS) – A two year follow-up study. J Neurol 2004; 251: 30-34
Escalating immunotherapy of multiple sclerosis. New aspects and practical application. Journal of Neurology 2004; 251: 1329-1339
Neue Therapieansätze bei Multipler Sklerose. Nervenheilkunde 2005; 4: 294-300
Predictive value of evoked potentials for long term disease course in Multiple Sclerosis. Multiple Sclerosis 2006; 12: 58-65
Isolation of Brucella melitensis from a patient with hearing loss. Eur J Clin Microbiol Infect Dis 2006; DOI 10.1007/s10096-006-0084-4
Immunmodulatorische Stufentherapie der Multiple Sklerose – aktuelle Therapieempfehlungen (September 2006). Nervenarzt 2006; 77: 1506-1518
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. J Neurol. 2008; 255:1449-1463
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. Akt Neurol 2009: DOI 10.1055/s−0029−1220429
Injektionshilfen in der Basistherapie der Multiplen Sklerose. Nervenheilkunde 2010; 1-2:57-62
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings. Akt Neurologie 2011; 38: 2 - 11
Multiple Sklerose – Ist eine Neuroprotektion mit aktuellen Therapien möglich? Neurotransmitter 10 / 2011; 34 – 41
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97.
Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose. Akt Neurol 2012; 39: 342–350
Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. Akt Neurol 2013; 40: 486–493
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.
Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten. DNP - Der Neurologe und Psychiater 2014; 15: 64-67
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015; 8(1):3-13. doi: 10.1177/1756285614560733.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001360. [Epub ahead of print]
Adherence to, and effectiveness of, sc IFN b-1a administered by RebiSmart in patients with RMS. Expert Opin. Drug Deliv. 2015; 12(8)
Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten. DNP – Der Neurologe und Psychiater, 2014:15 (12)
„Time is brain“ in relapsing remitting multiple sclerosis: Current treatment concepts inimmunotherapy. Der Nervenarzt 2015; 86: 1528-1537
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple Sclerosis. Acta Neuropathologica Communications (2016) 4:81- DOI 10.1186/s40478-016-0352-1
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). Therapeutic Advances in Neurological Disorders2018 Jan 23;11:1756285617749802. doi: 10.1177/1756285617749802.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: A multi-center observational study. Journal of Neurology, (https ://doi.org/10.1007/s0041 5-018-8871-2)
Dimethylfumarat – Therapiemanagement in der neurologischen Praxis. Thieme Praxis Report 2018; 10 (■): 1–12
Treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019, Vol. 12: 1–14
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother. 2020 Jul 13;1-5. doi:10.1080/14656566.2020.1792885.